Li Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
 
(50 intermediate revisions by the same user not shown)
Line 5: Line 5:
| width="60%" align="justify" style="border: 2px solid #6688aa; background-color:#cccccc; padding:1em;" class="plainlinks"|
| width="60%" align="justify" style="border: 2px solid #6688aa; background-color:#cccccc; padding:1em;" class="plainlinks"|
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
<div style="float:left;margin-left:0.3em;margin-right:0.7em">
== '''Please visit our new lab website [https://sites.uci.edu/weililab https://sites.uci.edu/weililab] ''' ==


== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  
== '''Computational Cancer Epigenomics and Transcriptomics (PI: Wei Li)''' ==  


[http://www.bcm.edu/cancercenter/ Dan L. Duncan Cancer Center], [http://www.bcm.edu/mcb/index.html Department of Molecular and Cellular Biology], [http://www.bcm.edu/ Baylor College of Medicine]
Division of Computational Biomedicine, Department of Biological Chemistry, School of Medicine, University of California, Irvine
 
*
</div>
</div>


Line 15: Line 16:


==Recent News==
==Recent News==
. 07/2017: Jianzhong's DNA methylation editing paper was published in  '''Nature Communications'''.
. 03/2021: Yipeng's single cell APA paper was accepted to '''Genome Research'''
 
. 05/2017: Our TCGA Liver Cancer paper was accepted to '''Cell'''.
 
. 02/2017: Our Research Center for Cancer Systems Biology '''(CCSB U54) grant''' was funded by NCI, in collaboration with Qianben Wang, Victor Jin and Tim Huang.
 
. 02/2017: Collaborative work with Xiaobing Shi and David Allis was accepted to '''Nature'''.
 
. 12/2016: Graduate student Xueqiu Lin will start his postdoc position at Stanford.
 
. 11/2016: Jianfeng Xu has passed his qualify exam. Congratulations!
 
. 08/2016: Welcome our new Postdoc Associates Drs. Xiaodong Cui, Jiejun Shi and Lei Li.
 
. 08/16: Zheng Xia will start his '''tenure-track faculty position''' at Oregon Health & Science University (OHSU) with a million-dollar package. Congratulations!


. 07/16: Wei has been '''promoted to Professor of Bioinformatics''' at Baylor College of Medicine.
. 02/2021: Lei's 3'aQTL paper entitled "An atlas of alternative polyadenylation quantitative trait loci contributing to complex trait and disease heritability" was accepted to '''Nature Genetics'''


. 06/16: Xueqiu successfully defended her PhD thesis. '''Congratulations Dr. Lin'''.
. 09/2020: Jie's DORGE cancer driver gene paper was accepted to '''Science Advances'''


. 06/16: A new paper w/ MG Lee @ MD Anderson was accepted to '''Molecular Cell'''.
. 08/2020: Jianfeng's CHALM methylation paper was accepted to '''Nature Communications'''


. 04/16: Jianzhong's DNMT3A/TET2 paper (w/ Goodell lab) was accepted to '''Nature Genetics'''.
. 08/2020: Cui Ya's [https://wlcb.oit.uci.edu/NG-Circos NG-Circos] paper was accepted to '''NAR Genomics and Bioinformatics'''


. 04/16: Wei has been selected as a recipient of the 2016 [https://www.bcm.edu/news/awards-honors-faculty-staff/2016-debakey-research-award-science  '''Michael E. DeBakey, M.D., Excellence in Research Award''']
. 01/2020: Our lab has moved to [https://start.emailopen.com/public1/BrView.aspx?idc=197231&cc1=j7WFn6r3B8J&s5=47494aca951f49d1b1531a572c5754f8WVUa880hkbx84Pd.343068638%40emailopen.com University of California Irvine]


. 04/16: Yuanxin has been offered a '''tenure-track faculty position''' at The University of Texas Health Science Center at Houston (UTHealth). Congratulations!
. 01/2020: Lei's paper w/ Ryan Potts was accepted to  '''Molecular Cell'''


. 03/2016: Ben's enhancer hypomethylation paper (w/ Goodell lab) was accepted to '''Cancer Cell'''.
. 10/2019: Collaborative work with David Allis and Wen Hong was accepted to '''Nature''';


. 02/2016: Yuanxin's SIRT6 paper (w/ Chua lab at Stanford) was accepted to '''Nature Structural & Molecular Biology'''
. 10/2019: Collaborative work with Suming Huang was accepted to '''Cancer Cell''';


. 01/2016: Welcome our new Postdoc Associate Dr. Jie Lyu.
. 9/2019: Collaborative work with Costa-Mattioli's group was accepted to '''Science'''; 


. 12/2015: Yuanxin's G9a paper (w/ Shi lab at MD Anderson) was accepted to '''Nature Communications. '''
. 05/2019: Collaborative work with Paolo Sassone-Corsi at UCI was published in '''Cell'''


. 12/2015: Kaifu's UTX paper (w/ Lee lab at MD Anderson) was accepted to '''Nucleic Acids Research '''.  
. 02/2019: Our new 5-year '''NCI R01 grant''' regarding DNA methylation canyon was funded.


. 11/2015: We received a new '''NIH/NCI R01''' grant (scored at 5%ile) to study 3`UTR alternations in human cancers.
. 07/2018: Jianzhong's DNA methylation canyon paper was accepted to '''Genome Biology'''.  


. 09/2015: Welcome our new Research Associate (and potential Graduate Student) YanBing Cheng.
. 06/2018: Jiejun’s paper was accepted to '''Nature Cell Biology'''.  


. 08/2015: Kaifu's Cancer Big-data analysis paper is published in '''Nature Genetics'''. This work links broad H3K4me3 to pan-cancer tumor suppressors. See reports in Nature Editor’s [http://blogs.nature.com/freeassociation/2015/08/methylation-marks-tumor-suppressors.html Blog], [http://cancerdiscovery.aacrjournals.org/content/early/2015/09/01/2159-8290.CD-RW2015-166.abstract Cancer Discovery], [http://www.ebiotrade.com/newsf/2015-8/2015825165005119.htm ebiotrade.com] (in Chinese), [http://fromthelabs.bcm.edu/2015/10/15/novel-epigenetic-signature-for-tumor-suppressors-in-normal-cells-found/ BCM news] and [http://cancer.osu.edu/news-and-media/news/studies-suggest-new-ways-to-inhibit-oncogenes-enhance-tumor-suppressor-activity OSU news]; and an error we found in a [http://www.cell.com/cell/fulltext/S0092-8674(15)01407-5 Cell paper].
. 06/2018: Xueqiu's DNMT3A binding paper was accepted to '''Genome Biology'''


. 07/2015: Wei will become a regular member of the '''NIH GCAT''' (Genomics, Computational Biology and Technology) study section.
. 03/2018: HJ Park's papers were accepted to '''PLOS Computational Biology''' and '''Cell Reports''', respectively.  


. 06/2015: Kaifu will start his '''tenure-track faculty''' position at Cornell University & Methodist Hospital. Congratulations!
. 01/2018: HJ Park's 3'UTR vs ceRNA paper was finally accepted to '''Nature Genetics''' after 1.5 years and 3 rounds of revisions/appeals. A good start to the new year!


. 03/2015:  Kaifu's MeCP2 mCH binding paper (w/ Zoghbi lab) is accepted to '''PNAS'''.


. 3/2015: We received a NEW '''CPRIT''' grant. 


. 01/2015:  Deqiang, HJ and Ben's HSC novel noncoding RNA paper is accepted to '''Cell Stem Cell''' -- the 100th paper we published.




Line 93: Line 77:
<div style="border-bottom: 1px dashed #9999CC;">
<div style="border-bottom: 1px dashed #9999CC;">


Our lab is focused on the design and application of bioinformatics algorithms to elucidate global epigenetic mechanisms and transcription dynamics in normal development and diseases such as cancer. Since establishing the lab in early 2008, we have  
Our lab is focused on the design and application of bioinformatics algorithms to elucidate global regulatory mechanisms in normal development and diseases such as cancer. We have a solid track record in large-scale genomics data analysis, and in developing widely used open-source bioinformatics software, such as MACS (>7,000 citations) for ChIP-seq and RSeqQC (>800 citations) for RNA-seq. In collaboration with experimental biologists, we have used bioinformatics to gain novel biological insights into development, aging, stem cell, neurologic disorders, and various cancers. Our areas of expertise include 1) DNA methylation using Bisulfite-seq; 2) Epigenetic regulation using ChIP-seq; 3) Alternative Polyadenylation (APA); 4) Non-coding RNA; 5) Nucleosome organization using MNase-seq. Since establishing our own bioinformatics lab in early 2008, we have (as of Febuary 2020)
* '''Published''' >95 peer-reviewed papers through solid methodology development and extensive collaboration research, including >37 in '''Nature, Science and Cell''' series.
* '''Published''' 143 peer-reviewed papers through solid methodology development and extensive collaboration research, including 20 senior-author papers in '''Nature''' and '''Cell''' series.  


* '''Been well-funded''' by NIH and Texas CPRIT with total external funding >$1.0 million per year. Dr Li is the PI on the following 3 major grants: NIH R01HG007538 (2013-2018) and R01CA193466 (2015-2020); CPRIT RP150292 (2015-2018).  
* '''Been well-funded''' with total external funding >$1.0 million per year, including 4 PI grants from NIH: NIH R01HG007538 (2013-2020)R01CA193466 (2015-2020), R01CA228140 (2019-2024) and  U54CA217297 (2017-2022).  
   
   
* '''Mentored''' the first 5 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US.
* '''Mentored''' the first 7 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US (6) and China (1).
 
We have developed a number of widely used algorithms to analyze next generation sequencing data from ChIP-seq (MACS, MACE), DNA methylation Bisulfite-seq (BSMAP/RRBSMAP, BSeQC, MOABS), nucleosome positioning MNase-seq (DANPOS), and RNA-seq (CPAT, RSeQC, DaPars). These algorithms have been broadly adopted by thousands of academic users. For example, the MACS algorithm has gathered >3000 citations since 2008.
 
In collaboration with experimental biologists, we used these algorithms to gain novel biological insights from various biological processes and disease models.


* '''Chromatin Factors''': ER in breast cancer, AR in prostate cancer, FoxA1 pioneer factor, Atoh1 in neuron development, NSD2 in oncogenic programming, SIRT7 in cancer transformation, ZM11 in transcription elongation, and p53 in ES differentiation..


* '''DNA Methylation''': DNA methylation Canyon, Epigenetic changes in HSC aging, Dnmt3a in HSC differentiation and cancer transformation.
* '''Nucleosome Organization''': Fragile nucleosome in stress-response, Promoter nucleosome with Tup1, Nucleosome dynamics in ES differentiation, and Global nucleosome loss in yeast aging.
* '''Transcriptome''': chimeric RNA in prostate cancer, Long non-coding RNA in HSC, 3’UTR deletion in cancer and its master regulator CFIm25. .


   
   
Line 124: Line 98:
|}
|}
</center>
</center>
<html>
<script type="text/javascript">


  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', 'UA-5924762-2']);
  _gaq.push(['_trackPageview']);


  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
 
</script>
</html>


__NOTOC__
__NOTOC__

Latest revision as of 22:26, 7 May 2021

Home        People        Publications        Collaborations        Software        Positions        Contact       


Recent News

. 03/2021: Yipeng's single cell APA paper was accepted to Genome Research

. 02/2021: Lei's 3'aQTL paper entitled "An atlas of alternative polyadenylation quantitative trait loci contributing to complex trait and disease heritability" was accepted to Nature Genetics

. 09/2020: Jie's DORGE cancer driver gene paper was accepted to Science Advances

. 08/2020: Jianfeng's CHALM methylation paper was accepted to Nature Communications

. 08/2020: Cui Ya's NG-Circos paper was accepted to NAR Genomics and Bioinformatics

. 01/2020: Our lab has moved to University of California Irvine

. 01/2020: Lei's paper w/ Ryan Potts was accepted to Molecular Cell

. 10/2019: Collaborative work with David Allis and Wen Hong was accepted to Nature;

. 10/2019: Collaborative work with Suming Huang was accepted to Cancer Cell;

. 9/2019: Collaborative work with Costa-Mattioli's group was accepted to Science;

. 05/2019: Collaborative work with Paolo Sassone-Corsi at UCI was published in Cell

. 02/2019: Our new 5-year NCI R01 grant regarding DNA methylation canyon was funded.

. 07/2018: Jianzhong's DNA methylation canyon paper was accepted to Genome Biology.

. 06/2018: Jiejun’s paper was accepted to Nature Cell Biology.

. 06/2018: Xueqiu's DNMT3A binding paper was accepted to Genome Biology

. 03/2018: HJ Park's papers were accepted to PLOS Computational Biology and Cell Reports, respectively.

. 01/2018: HJ Park's 3'UTR vs ceRNA paper was finally accepted to Nature Genetics after 1.5 years and 3 rounds of revisions/appeals. A good start to the new year!




News Archive




Our lab is focused on the design and application of bioinformatics algorithms to elucidate global regulatory mechanisms in normal development and diseases such as cancer. We have a solid track record in large-scale genomics data analysis, and in developing widely used open-source bioinformatics software, such as MACS (>7,000 citations) for ChIP-seq and RSeqQC (>800 citations) for RNA-seq. In collaboration with experimental biologists, we have used bioinformatics to gain novel biological insights into development, aging, stem cell, neurologic disorders, and various cancers. Our areas of expertise include 1) DNA methylation using Bisulfite-seq; 2) Epigenetic regulation using ChIP-seq; 3) Alternative Polyadenylation (APA); 4) Non-coding RNA; 5) Nucleosome organization using MNase-seq. Since establishing our own bioinformatics lab in early 2008, we have (as of Febuary 2020)

  • Published 143 peer-reviewed papers through solid methodology development and extensive collaboration research, including 20 senior-author papers in Nature and Cell series.
  • Been well-funded with total external funding >$1.0 million per year, including 4 PI grants from NIH: NIH R01HG007538 (2013-2020), R01CA193466 (2015-2020), R01CA228140 (2019-2024) and U54CA217297 (2017-2022).
  • Mentored the first 7 postdoc trainees to start their tenure track faculty positions in prestigious research institutions in the US (6) and China (1).



Lab Intranet openwetware